Common Contracts
7 similar Underwriting Agreement contracts by Collegium Pharmaceutical, Inc, GLADSTONE LAND Corp, Intec Pharma Ltd., others
6,818,182 Shares SYNDAX PHARMACEUTICALS, INC. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT December 6, 2022Underwriting Agreement • December 7th, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
18,026,315 Shares of Common Stock And Pre-Funded Warrants to Purchase 12,921,055 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 4th, 2022 • Rezolute, Inc. • Pharmaceutical preparations • New York
Introductory. Rezolute, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 18,026,315 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), (ii) Class A warrants of the Company (in the form attached hereto as Exhibit C-1) to purchase 1,973,684 shares of Common Stock (the “Class A Pre-Funded Warrants”), and (iii) Class B warrants of the Company (in the form attached hereto as Exhibit C-2) to purchase 10,947,371 shares of Common Stock (the “Class B Pre-Funded Warrants” and, together with the Class A Pre-Funded Warrants, the “Pre-Funded Warrants”). The Shares and the Pre-Funded Warrants to be sold by the Company are collectively referred to as the “Securities.” Jefferies LLC (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Secur
2.625% Convertible Senior Notes due 2026 Collegium Pharmaceutical, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 13th, 2020 • Collegium Pharmaceutical, Inc • Pharmaceutical preparations • New York
Change If a make-whole fundamental change occurs and the conversion date for the conversion of a Note occurs during the related make-whole fundamental change conversion period, then, subject to the provisions described in the Preliminary Prospectus Supplement under the caption “Description of Notes—Conversion Rights—Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change,” the conversion rate applicable to such conversion will be increased by a number of shares set forth in the table below corresponding (after interpolation, as described below) to the make-whole fundamental change effective date and the stock price of such make-whole fundamental change:
Intec Pharma Ltd. 15,280,000 Ordinary Shares Pre-Funded Warrants to Purchase 970,000 Ordinary Shares Ordinary Warrants to Purchase 16,250,000 Ordinary Shares Underwriting Agreement (this “Agreement”)Underwriting Agreement • February 3rd, 2020 • Intec Pharma Ltd. • Pharmaceutical preparations
Intec Pharma Ltd., a company organized and existing under the laws of the State of Israel, public company number 513022780 (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of (a) 15,280,000 ordinary shares (the “Firm Shares”), no par value, of the Company (the “Ordinary Shares”), (b) 970,000 pre-funded warrants to purchase 970,000 Ordinary Shares at an exercise price of $0.001 per share (the “Pre-Funded Warrants”) and (c) warrants to purchase 16,250,000 Ordinary Shares at an exercise price of $0.40 per share (the “Ordinary Warrants” and, collectively with the Pre-Funded Warrants and the Firm Shares, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by each Underwriter is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to each Underwriter, at the option of such Underwriter, up to (i) an additional 2,437,500 Ordinary Shares (the “Option Shares”
Sol-Gel Technologies Ltd. 1,250,000 Ordinary Shares (Par Value NIS 0.1 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • August 8th, 2019 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York
Introductory. Sol-Gel Technologies Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 1,250,000 ordinary shares of the Company, par value NIS 0.1 per share (the “Ordinary Shares”). The 1,250,000 Ordinary Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 187,500 Ordinary Shares as provided in Section 2. The additional 187,500 Ordinary Shares to be sold pursuant to such option are called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To
PLURISTEM THERAPEUTICS INC. 27,142,858 Shares and Warrants to purchase 27,142,858 Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 6th, 2019 • Pluristem Therapeutics Inc • Biological products, (no disgnostic substances) • New York
PLURISTEM THERAPEUTICS INC., a Nevada corporation (the “Company”), proposes to issue and sell to Ladenburg Thalmann & Co. Inc. (the “Representative”) and the other underwriters listed on Schedule I hereto (collectively, with the Representative, the “Underwriters”), pursuant to and in accordance with the terms and conditions of this underwriting agreement (the “Agreement”) in a public offering (the “Offering”), an aggregate of 27,142,858 shares (the “Shares”) of its common stock, par value $0.00001 per share (the “Common Stock”), and warrants (each whole warrant, a “Warrant”) to purchase up to an aggregate of 27,142,858 shares of Common Stock. The Shares to be sold by the Company are called the “Firm Shares.” The Firm Shares and the Warrants will be sold as units (the “Units”), with each Unit consisting of one Share and a Warrant to purchase one Share. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,428,571 Shares as provided in Secti
Shares of Common Stock Gladstone Land Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • May 15th, 2015 • GLADSTONE LAND Corp • Real estate investment trusts • New York
